SABCS 2023
YiR in EBC #2: De-escalating therapy in locoregional recurrence, adjuant therapy with CDK4/6i and new insights in pregnancy/fertility preservation after EBC
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304, Oxford analyses ASCO23, monarchE, NATALEE, POSITIVE (SABCS22 &23)
SABCS 2023
YiR in EBC #2: De-escalating therapy in locoregional…
KATHERINE, PHERGain (ASCO23), KEYNOTE-522, ALEXANDRA/IMpassion030, KEYNOTE-756 (ESMO&SABCS), CheckMate-7FL
SABCS 2023
YiR in EBC #1: New data in HER2+ and Immunotherapy in…
BEGONIA, SAFIR02-Breast, HER2CLIMB02, KATHERINE, COMPASS, DESTINY-Breast -01, -02, -03, TULIP, monarcHER
SABCS 2023
YiR in ABC #1: Exciting new data for first line mTNBC,…
SONIA, monarch3, PARSIFAL-long, INAVO120, RIGHT-Choice, PALMIRA, EMERALD, CAPItello291
SABCS 2023
YiR in ABC #2: New data on treatment in metastatic HR+…
DESTINY-Breast 04, TROPiCS-02, TROPION-Breast01
SABCS 2023
YiR in ABC #3: Exciting new data on ADCs in HR+ breast…
NATALEE
SABCS 2023
Final iDSF analysis in NATALEE
CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 highlights in early breast cancer
ADAPTcycle
SABCS 2023
ADAPTcycle - endocrine response
NATALEE
SABCS 2023
An enrichment of therapy options in the endocrine…
CheckMate 7FL, KEYNOTE-756
SABCS 2023
Hope with CPI for luminal breast cancer
KEYNOTE-756
SABCS 2023
Prediction of pCR in KEYNOTE-756
KEYNOTE-756
SABCS 2023
KEYNOTE-756 - Subgroup analysis
CheckMate 7FL
SABCS 2023
CheckMate7FL - Biomarker
monarchE
SABCS 2023
cTDNA analyses in monarchE
KATHERINE
SABCS 2023
KATHERINE: OS improvement in HER2+ eBC
KATHERINE
SABCS 2023
T-DM1 in post-neoadjuvant therapy now also with…
SURVIVE, SURVIVE HERoes
SABCS 2023
Change in the standard of follow-up care?
ALEXANDRA/IMpassion030
SABCS 2023
Immunotherapy for early TNBC must be neoadjuvant
SABCS 2023
Pregnancy after BC is safe - also in germline BRCA+ pts
POSITIVE
SABCS 2023
Pregnancy despite endocrine therapy in HR+ breast…
POSITIVE
SABCS 2023
Importance of the onco-fertility discussion
SABCS 2023
Anthtracyclines in EBC: to give or not to give?
monarchE
SABCS 2023
Análisis de cTDNA en monarchE
CheckMate756, KEYNOTE-756, POSITIVE
SABCS 2023
SABCS23 evidenzia il cancro al mammario in fase precoce
KATHERINE
SABCS 2023
KATHERINE : amélioration de la survie globale dans le…
SABCS 2023
Gravidanza dopo la diagnosi di carcinoma mammario è…
POSITIVE
SABCS 2023
Importância da discussão sobre onco-fertilidade
MONARCH 3
SABCS 2023
Final OS analysis in MONARCH 3
MONARCH 3
SACBS 2023
MONARCH 3 shows clinically relevant OS-benefit without…
DESTINY-Breast08
SABCS 2023
T-DXd + endocrine therapy interesting for HR+ HER2low…
FOENIX-MBC2 study
SABCS 2023
Fulvestrant + futibatinib interesting for FGFR1…
PARSIFAL-LONG
SABCS 2023
Letrozole + palbo as effective as fulvestrant + palbo
MONARCH 3
SABCS 2023
Is OS important?
MONARCH 3
SABCS 2023
Does abemciclib lead to improved OS survival in the 1st…
INAVO120
SABCS 2023
Promising data for the PIK3CA-inhibitor inavolisib
PARSIFAL-LONG
SABCS 2023
OS benefit with fulvestrant/letrozole + palbocilib is…
INAVO120
SASBCS 2023
PIK3CA-inhibitor: positive results in Phase III
MONARCH 3
SABCS 2023
SABCS23 highlights in metastatic breast cancer
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant in HR+ HER2-…
TROPION-Breast01
SABCS 2023
Dato-Dxd achieves PFS
PARSIFAL-LONG
SABCS 2023
Long follow-up of CDK4/6i
AVIATOR/TBCRC045
SABCS 2023
Avelumab appears to be effective in HER2+ mBC
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1 interesting for specific patients
HER2CLIMB-02
SABCS 2023
New potential backbone for tucatinib in mHER2+ BC
ASPIRE
SABCS 2023
Effective, chemo-free combination for triple-positive…
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possible role in the contemporary…
HER2CLIMB-02
SABCS 2023
Efficacy of tucatinib confirmed, but unclear for which…
KEYLYNK-009
SABCS 2023
KEYLYNK-009: Pembrolizumab + olaparib a well-tolerated…
SENOMAC
SABCS 2023
Axillary surgery de-escalation
NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Axillary radiotherapy can be omitted in T3N1 BC pts
PREFERABLE-EFFECT
SABCS 2023
Physical acitivity improves QoL in advanced BC
PREFERABLE-EFFECT
SABCS 2023
Metastatic patients can and must exercise
SENOMAC
SABCS 2023
Positive sentinel lymph node after mastectomy
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Rethinking management of the axilla
ICARO
SABCS 2023
Isolated tumor cells in the sentinel lymph node - does…
OLAnzaPiNE
SABCS 2023
Low-dose olanzapine more favorable in the prophylaxis…
ADAPTcycle
SABCS 2023
Poster insights: PO4-01-10 ADAPTcycle
PARSIFAL-LONG
SABCS 2023
La supervivencia obtenida con palbociclib y…
HER2CLIMB-02
SABCS 2023
Tucatinib + T-DM1: Possibile un ruolo nello scenario…
NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
La radioterapia ascellare può essere omessa nelle…
TROPION-Breast01
SABCS 2023
Dato-Dxd consigue PFS
SENOMAC, NRG Oncology/NSABP B-51/RTOG 1304
SABCS 2023
Duże zmiany w leczeniu pachy
INAVO120
SABCS 2023
Inhibiteur de PIK3CA: résultats positifs en phase III
SENOMAC
SABCS 2023
Desescalada de cirugía axilar
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant nel carcinoma…
CAPItello-292
SABCS 2023
Capiversatib + Palbociclib + Fulvestrant dans le cancer…
PREFERABLE-EFFECT
SABCS 2023
L'attività fisica migliora la qualità di vita nel…
HER2CLIMB-02
SABCS 2023
Tukatynib skuteczny, ale czy umiemy określić jego…
MONARCH 3
SABCS 2023
SABCS23 evidenzia nel cancro al mammario metastatico
HER2CLIMB-02
SABCS 2023
New and good therapy options for HER2+ patients
MONARCH 3
SABCS 2023
No significant OS - but what is the impact on clincial…
CheckMate-7FL, Keynote-756, ALEXANDRA/IMpassio030, KEYLYNK-009
SABCS 2023
Immunotherapy and combination therapies for HR+/HER2-…
NRG Oncology, NSABP B-51, RTOG 1304
SABCS 2023
De-escalation of radiotherapy after neoadjuvant therapy
POSITIVE
SABCS 2023
Pregnancy is safe after endocrine therapy
OPBC05/EUBREAST-14R/ICARO, SENOMAC
SABCS 2023
DE-escalation of the axillary interverntion after…
TROPION-Breast01
SABCS 2023
Good balance between benefits and side effect - but not…
Katherine
SABCS 2023
OS and final iDFS data - confirming data but risk and…
INAVO120
SABCS 2023
PI3K inihbitor Inavolisib shows improved PFS - one step…
NATALEE, monarchE
SABCS 2023
Final iDFS data - is everything clear yet?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!